

May 6-8, 2002 • Wyndham Baltimore Inner Harbor • Baltimore, MD

*The Fifth Annual Conference*  
on  
**Vaccine  
Research**

- Basic Science
- Product Development
- Clinical & Field Studies

Call For Abstracts and Conference Announcement

SPONSORED BY:



National Foundation for Infectious Diseases

IN COLLABORATION WITH:



Centers for Disease  
Control and Prevention



National Institute of Allergy  
and Infectious Diseases



International Society  
for Vaccines



United States  
Department of  
Agriculture



Center for Biologics  
Evaluation and Research  
Food and Drug Administration



Albert B. Sabin  
Vaccine Institute



Center for Vaccine  
Development,  
University of Maryland



World Health  
Organization

# The Fifth Annual Conference

## Conference Overview

Every day's news brings reports of a host of scientific breakthroughs: new molecules described, gene sequences published, and cell signaling and regulatory networks unraveled. The pace of discovery is unprecedented and the implications of these discoveries for human and animal health stagger the imagination. Many of these scientific advances have the potential to contribute to the development of new or improved vaccines to prevent infectious and even non-infectious diseases.

Because vaccine research proceeds rapidly on multiple fronts, the Annual Conference on Vaccine Research has become the premier, international venue for vaccine researchers. Like its predecessors, the Fifth Annual Conference on Vaccine Research will be a multidisciplinary scientific forum addressing a broad array of cutting edge issues in vaccine research. Leading international experts will offer seminars and panel discussions on basic immunology, vaccine development, clinical testing, and vaccine regulation. These presentations along with submitted symposia, panel discussions, and submitted posters will encourage the networking and scientific collaboration so critical to advancing vaccine science.

## CONFERENCE OBJECTIVES

At the conclusion of this conference, participants should be able to meet the following session-specific objectives:

### Keynote Address

- Describe the critical role that vaccines might play in countering biological weapons.

### Mary Lou Clements-Mann Memorial Lecture in Vaccine Sciences

- Identify the opportunities and challenges associated with efforts to eliminate tuberculosis globally.

### Induction of Sustained Immune Responses:

#### Role of Immunological Memory

- Describe the immunological basis for inducing immunological memory at the T cell level.
- Define the rules for the establishment and maintenance of B cell memory and the persistence of the antibody response.
- Describe ways to assess immunological memory after human vaccination and discuss the importance of memory in achieving protection.
- Identify specific features of vaccine-induced immunological memory in the context of mucosal infection and vaccination.

### HIV/AIDS Vaccines – Basic Science Promise, Clinical Research Progress

- Describe various HIV antigens proposed as vaccine candidates and their induction of cytotoxic T cells and neutralizing antibodies.
- Discuss the implications of primate responses to surrogate HIV retrovirus vaccines for developing a human AIDS vaccine.
- Discuss the challenges likely to be encountered in utilizing an AIDS vaccine, once one is found to be efficacious in phase III trials.

### Economically Important Diseases of Food Animals

- Describe the 2001 outbreak of foot-and-mouth disease in the United Kingdom.
- Discuss the development of foot-and-mouth disease vaccines and the advantages and disadvantages associated with their use.
- Discuss vaccination of poultry against two viral respiratory diseases: avian influenza and Newcastle disease.
- Review current practices and challenges to the routine vaccination of poultry against herpes virus-induced lymphomas.
- Describe the use of vaccines to control herpes virus diseases in cattle.

### Basic Immunology for Vaccine Development

- Describe the toll receptor and its role in triggering immune responses to vaccines.
- Discuss the role of the CpG oligonucleotide in stimulating the immune response to microbial DNA vaccines.
- Review the use of heat shock proteins as vaccine adjuvants.
- Describe the presentation of microbiolipid and glycolipid-containing antigens by CD1 molecules.

### The Global Alliance for Vaccines and Immunization – Research & Development Agenda

- Characterize the research and development programs of the Global Alliance for Vaccines and Immunization.
- Discuss recent scientific efforts to develop an improved rotavirus vaccine.
- Review research to develop pneumococcal vaccines against clinically relevant isolates not targeted by current vaccines.
- Describe how research may lead to greater use of meningococcal vaccines.
- Discuss how technological advances are leading to new ways for administering vaccines.

### Human Papillomavirus

- Describe the basic biology, epidemiology, and clinical implications of papillomavirus vaccines.
- Identify appropriate endpoints for phase III evaluations of papillomavirus vaccines.
- Review the findings of current clinical trials of papillomavirus vaccines.
- Discuss the development and role of therapeutic vaccines for treating papillomavirus infections.

### New Vaccine Technologies

- Describe how transgenic animal technology can be used to produce vaccines.
- Discuss how biotechnology is being used to incorporate vaccines into plant foods.
- Discuss recent scientific advances in DNA vaccine development.
- Review how gene shuffling technology is being applied to vaccine development.

### Practical Issues in Clinical Trials

- Discuss the safety considerations in the design of clinical trials.
- Discuss how clinical trials might be designed to assess for herd immunity.
- Discuss issues related to post study obligations to research study participants.

# on Vaccine Research

## EXHIBIT HALL

*The conference will feature an exhibit hall.  
If you would like to obtain an Exhibitor Prospectus  
for your organization, please contact:*

**Kathy Hanrahan**

NFID (attn: ACVR Exhibits)

4733 Bethesda Avenue, Suite 750 • Bethesda, MD 20814 USA

Tel. 301-656-0003 x19 • Fax 301-907-0878

E-Mail [khanrahan@nfid.org](mailto:khanrahan@nfid.org)

## WHO SHOULD ATTEND?

- Researchers and Scientists
- Molecular Biologists
- Epidemiologists
- Public Health Officials
- Microbiologists
- Physicians and Veterinarians
- Immunologists
- Vaccine Manufacturers

Conference participants should have a knowledge of or interest in vaccine research.

## ACKNOWLEDGMENTS (as of November 5, 2001)

This conference is supported, in part, through unrestricted educational grants from:

- AlphaVax
- Becton Dickinson
- GenVec, Inc
- Powderject Vaccines
- Wyeth Lederle Vaccines
- Aventis Pasteur
- BioSante Pharmaceuticals
- GlaxoSmithKline
- Shire Biologics
- Aviron
- Chiron
- MedImmune
- VaxGen
- Baxter Healthcare
- Dynport Vaccine Company LLC
- Merck Vaccine Division
- Vical

## CME ACCREDITATION STATEMENT

The National Foundation for Infectious Diseases (NFID) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education (CME) for physicians. NFID takes responsibility for the content, quality, and scientific integrity of this CME activity.

## CME CREDIT STATEMENT

The National Foundation for Infectious Diseases (NFID) designates this CME activity for a maximum of 20 credit hours in Category 1 of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

# The Fifth Annual Conference

## CONFERENCE CO-CHAIRS

**William J. Martone, M.D.**  
*Senior Executive Director*  
National Foundation for Infectious Diseases  
Bethesda, Maryland

**Peter L. Nara, D.V.M., Ph.D.**  
*Immediate Past President*  
International Society for Vaccines  
and  
*Chief Executive Officer for Research  
and Development*  
Biological Mimetics, Inc.  
Frederick, Maryland

**N. Regina Rabinovich, M.D.**  
*Director, Malaria Vaccine Initiative*  
Program for Appropriate Technology in Health  
Rockville, Maryland

**Bruce G. Weniger, M.D.**  
*Assistant Chief for Vaccine Development*  
Vaccine Safety and Development Branch  
National Immunization Program  
Centers for Disease Control and Prevention  
Atlanta, Georgia

## SCIENTIFIC PROGRAM COMMITTEE

**Jacques Banchereau, Ph.D.**  
*Director*  
*Max and Gayle Clappitt Chair for  
Immunology Research*  
Baylor Institute for Immunology Research  
Dallas, Texas

**Michel De Wilde, Ph.D.**  
*Executive Vice President, Research  
and Development*  
Aventis Pasteur  
Swiftwater, Pennsylvania

**Richard J. Duma, M.D., Ph.D.**  
*Director of Infectious Diseases*  
Halifax Medical Center  
Daytona Beach, Florida

**Colonel Charles H. Hoke, Jr.,  
M.D., M.C.**  
*Manager, Military Infectious Disease  
Research Program*  
U.S. Army Medical Research  
and Materiel Command  
Fort Detrick, Maryland

**Diane E. Griffin, M.D., Ph.D.**  
*Professor and Chair*  
W. Harry Feinstone Department of Molecular  
Microbiology and Immunology  
Johns Hopkins University Bloomberg  
School of Public Health  
Baltimore, Maryland

**Paul-Henri Lambert, M.D.**  
*Professor, Centre of Vaccinology*  
Centre Medical Universitaire de Genève  
Geneva, Switzerland

**Myron M. Levine, M.D.,  
D.T.P.H.**  
*Professor and Director, Center for Vaccine  
Development*  
University of Maryland School of Medicine  
Baltimore, Maryland

**Brian W. J. Mahy, Ph.D.,  
Sc.D., D.Sc.**  
*Senior Scientist, Office of the Director*  
National Center for Infectious Diseases  
Centers for Disease Control and Prevention  
Atlanta, Georgia

**William J. Martone, M.D.**  
*Conference Co-Chair*

**Gary J. Nabel, M.D., Ph.D.**  
*Director*  
Dale and Betty Bumpers Vaccine  
Research Center  
National Institutes of Health  
Bethesda, Maryland

**Peter L. Nara, D.V.M., Ph.D.**  
*Conference Co-Chair*

**David A. Neumann, Ph.D.**  
*Associate Director*  
National Foundation for Infectious Diseases  
Bethesda, MD

**Stanley A. Plotkin, M.D.**  
*Medical and Scientific Advisor*  
Aventis Pasteur  
and  
*Emeritus Professor of Pediatrics*  
University of Pennsylvania  
Doylestown, Pennsylvania

**Gregory A. Poland, M.D.**  
*President*  
International Society for Vaccines  
and  
*Associate Director for Research*  
Mayo Clinic and Foundation  
Rochester, Minnesota

**N. Regina Rabinovich, M.D.**  
*Conference Co-Chair*

**Harriet L. Robinson, Ph.D.**  
*Asa Griggs Candler Professor*  
*Chief, Division of Microbiology and  
Immunology*  
Yerkes Regional Primate Research Center  
Emory University  
Atlanta, Georgia

**Connie Schmaljohn, Ph.D.**  
*Chief, Department of Molecular Virology*  
Virology Division  
U.S. Army Medical Research Institute of  
Infectious Diseases  
Ft. Detrick, Maryland

**Ethan M. Shevach, M.D.**  
*Head, Cellular Immunology Section*  
Laboratory of Immunology  
National Institute of Allergy and  
Infectious Diseases  
National Institutes of Health  
Bethesda, Maryland

**George R. Siber, M.D.**  
*Vice President*  
Wyeth Lederle Vaccines  
Pearl River, New York

**David E. Swayne, D.V.M., Ph.D.**  
*Director, Southeast Poultry Research  
Laboratory*  
Agricultural Research Service  
U.S. Department of Agriculture  
Athens, Georgia

**Bruce G. Weniger, M.D.**  
*Conference Co-Chair*

**Kathryn C. Zoon, Ph.D.**  
*Director, Center for Biologics Evaluation  
and Research*  
U.S. Food and Drug Administration  
Rockville, Maryland

## CONFERENCE ORGANIZING COMMITTEE

**M.-Teresa Aguado, M.D.**  
*Acting Director, Vaccine Development*  
Department of Vaccines and Other Biologicals  
World Health Organization  
Geneva, Switzerland

**Don L. Douglas**  
*President*  
Albert B. Sabin Vaccine Institute  
Washington, D.C.

**William J. Martone, M.D.**  
*Conference Co-Chair*

**Pamela M. McInnes, D.D.S.**  
*Deputy Director, Division of Microbiology  
and Infectious Diseases*  
National Institute of Allergy and  
Infectious Diseases  
National Institutes of Health  
Bethesda, Maryland

**Peter L. Nara, D.V.M., Ph.D.**  
*Conference Co-Chair*

**David A. Neumann, Ph.D.**  
*Chair, Scientific Program Committee*  
*Chair, Conference Organizing Committee*

**N. Regina Rabinovich, M.D.**  
*Conference Co-Chair*

**David E. Swayne, D.V.M.,  
Ph.D.**  
*Member, Scientific Program Committee*

**Bruce G. Weniger, M.D.**  
*Conference Co-Chair*

**Kathryn C. Zoon, Ph.D.**  
*Member, Scientific Program Committee*



# The Fifth Annual Conference

## PRELIMINARY PROGRAM\*

Sunday, May 5, 2002

7:00 p.m. - 9:00 p.m. REGISTRATION

Monday, May 6, 2002

7:00 a.m. - 9:00 a.m. REGISTRATION AND POSTER SET-UP

8:30 a.m. CONTINENTAL BREAKFAST

9:00 a.m. WELCOME AND INTRODUCTIONS

### KEYNOTE ADDRESS

9:10 a.m. VACCINES AGAINST BIOTERRORISM  
(To Be Announced)

9:45 a.m. QUESTIONS AND ANSWERS

### MARY LOU CLEMENTS-MANN MEMORIAL LECTURE IN VACCINE SCIENCES

9:50 a.m. TUBERCULOSIS: PROGRESS IN THE DEVELOPMENT  
OF A NEW VACCINE AGAINST THE CAPTAIN OF  
ALL THE MEN OF DEATH  
Marcus A. Horwitz, M.D.  
*University of California*

10:25 a.m. QUESTIONS AND ANSWERS

10:30 a.m. COFFEE BREAK

### SYMPOSIUM 1: INDUCTION OF SUSTAINED IMMUNE RESPONSES: ROLE OF IMMUNOLOGICAL MEMORY

11:00 a.m. T-CELL MEMORY  
Rafi Ahmed, Ph.D.  
*Emory University School of Medicine*

11:15 a.m. QUESTIONS AND ANSWERS

11:20 a.m. B-CELL MEMORY AND PERSISTENCE OF  
ANTIBODY RESPONSES  
Ian MacLennan, M.B., Ph.D.,  
FRCPATH, FRCP  
*University of Birmingham,  
United Kingdom*

11:35 a.m. QUESTIONS AND ANSWERS

11:40 a.m. ROLE OF MEMORY IN VACCINE INDUCED  
PROTECTION  
Claire-Anne Siegrist, M.D.  
*University of Geneva*

11:55 a.m. QUESTIONS AND ANSWERS

12:00 p.m. MEMORY AT MUCOSAL LEVEL  
Myron M. Levine, M.D., D.T.P.H.  
*University of Maryland  
School of Medicine*

12:15 p.m. QUESTIONS AND ANSWERS

12:20 p.m. LUNCH

### SUBMITTED PRESENTATIONS

1:45 p.m. CONCURRENT SUBMITTED PRESENTATIONS

3:15 p.m. COFFEE BREAK

### SYMPOSIUM 2: AIDS VACCINES — BASIC SCIENCE PROMISE, CLINICAL RESEARCH PROGRESS

3:45 p.m. NEW DESIGNS FOR HIV VACCINES: ANTIGENS OF  
PROMISE FOR CTL AND BROADLY NEUTRALIZING  
ANTIBODIES  
Gary J. Nabel, M.D., Ph.D.  
*National Institutes of Health*

4:10 p.m. QUESTIONS AND ANSWERS

4:15 p.m. RECENT PRIMATE TRIALS — CLEAR FORKS IN THE  
PATH TOWARDS AN AIDS VACCINE  
Harriet L. Robinson, Ph.D.  
*Emory University School of Medicine*

4:40 p.m. QUESTIONS AND ANSWERS

4:45 p.m. EFFICACY TRIALS: UPDATE THEIR STATUS  
AND WHAT HAPPENS WHEN ONE WORKS?

#### (PANEL DISCUSSION)

José G. Esparza, M.D., Ph.D.  
(Panel Chair)  
*World Health Organization*

# on Vaccine Research

Donald P. Francis, M.D., D.Sc.  
*VaxGen, Inc.*

Lawrence Corey, M.D.  
*Fred Hutchinson Cancer  
Research Center*

Timothy D. Mastro, M.D.  
*Centers for Disease Control  
and Prevention*

Deborah L. Birx, M.D.  
*Walter Reed Army Institute of Research*

Paulo Roberto Teixeira  
*Ministério da Saúde, Brasil*

Patricia Fast, M.D., Ph.D.  
*International AIDS Vaccine Initiative*

5:20 p.m. DISCUSSION, QUESTIONS AND ANSWERS (PANEL)

5:50 p.m. ADJOURNMENT

6:00 p.m. POSTER AND EXHIBIT RECEPTION

## Tuesday, May 7, 2002

7:00 a.m.- 8:00 a.m. REGISTRATION

7:30 a.m. CONTINENTAL BREAKFAST

### SYMPOSIUM 3: ECONOMICALLY IMPORTANT DISEASES OF FOOD ANIMALS

8:00 a.m. THE FOOT-AND-MOUTH DISEASE EPIDEMIC IN THE UNITED KINGDOM, 2001. WHY VACCINATION WAS NOT EMPLOYED  
Alex I. Donaldson, MA, MVB, Ph.D., ScD, MRCVS  
*BBSRC Institute for Animal Health*

8:15 a.m. QUESTIONS AND ANSWERS

8:20 a.m. VACCINATION AGAINST FOOT-AND-MOUTH DISEASE  
Marvin J. Grubman, Ph.D.  
*U.S. Department of Agriculture*

8:35 a.m. QUESTIONS AND ANSWERS

8:40 a.m. VACCINATION AGAINST RESPIRATORY DISEASES OF POULTRY: AVIAN INFLUENZA AND NEWCASTLE DISEASE

David E. Swayne, D.V.M., M.Sc., Ph.D.  
*U.S. Department of Agriculture*

8:55 a.m. QUESTIONS AND ANSWERS

9:00 a.m. VACCINATION OF POULTRY: THE SPECIAL CASE OF MAREK'S DISEASE — HERPES VIRUS-INDUCED LYMPHOMAS

Richard L. Witter, D.V.M., Ph.D.  
*U.S. Department of Agriculture*

9:15 a.m. QUESTIONS AND ANSWERS

9:20 a.m. CONTROL OF BOVINE HERPESVIRUS DISEASES  
Lorne A. Babiuk, Ph.D.  
*University of Saskatchewan*

9:35 a.m. QUESTIONS AND ANSWERS

### SUBMITTED PRESENTATIONS

9:45 a.m. CONCURRENT SUBMITTED PRESENTATIONS

10:30 a.m. COFFEE BREAK

11:00 a.m. CONCURRENT SUBMITTED PRESENTATIONS

12:15 p.m. LUNCH

### SUBMITTED PRESENTATIONS (CONCURRENT)

1:30 p.m. SUBMITTED PRESENTATIONS

2:50 p.m. COFFEE BREAK

### SYMPOSIUM 4: BASIC IMMUNOLOGY FOR VACCINE DEVELOPMENT (CONCURRENT)

1:30 p.m. ROLE OF CpG OLIGONUCLEOTIDES IN DNA VACCINES  
Heather Davis, Ph.D.  
*Coley Pharmaceutical*

1:45 p.m. QUESTIONS AND ANSWERS

1:50 p.m. ANTIGEN PRESENTATION BY CD1 MOLECULES  
Michael Brenner, M.D.  
*Harvard Medical School*

# The Fifth Annual Conference

- 2:05 p.m. QUESTIONS AND ANSWERS
- 2:10 p.m. THE TOLL RECEPTOR IN IMMUNITY  
Alan Aderem, Ph.D.  
*University of Washington*
- 2:25 p.m. QUESTIONS AND ANSWERS
- 2:30 p.m. HEAT SHOCK PROTEINS AS ADJUVANTS  
Pramod Srivastava, Ph.D.  
*University of Connecticut  
School of Medicine*
- 2:45 p.m. QUESTIONS AND ANSWERS
- 2:50 p.m. COFFEE BREAK

## SYMPOSIUM 5: THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION – RESEARCH & DEVELOPMENT AGENDA

- 3:30 p.m. OVERVIEW OF THE RESEARCH AND DEVELOPMENT ACTIVITIES OF THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION  
Myron M. Levine, M.D., D.T.P.H.  
*University of Maryland School of Medicine*
- 3:45 p.m. QUESTIONS AND ANSWERS
- 3:50 p.m. ROTAVIRUS VACCINE DEVELOPED BY THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATIONS  
Roger I. Glass, M.D., Ph.D.  
*Centers for Disease Control and Prevention*
- 4:05 p.m. QUESTIONS AND ANSWERS
- 4:10 p.m. ACCELERATING PNEUMOCOCCAL CONJUGATE VACCINE DEVELOPMENT & USE: THE G.A.V.I. STRATEGY  
Orin S. Levine, Ph.D.  
*National Institutes of Health*
- 4:25 p.m. QUESTIONS AND ANSWERS

- 4:30 p.m. MENINGOCOCCAL A/C VACCINE PROJECT  
E. Marc LaForce, M.D.  
*Program for Appropriate Technology and Health (PATH) - Europe*
- 4:45 p.m. QUESTIONS AND ANSWERS
- 4:50 p.m. VACCINE TECHNOLOGY DEVELOPMENT BY THE GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION  
Gordon Dougan, M.S., D.Phil  
*Imperial College of Science, Technology & Medicine*
- 5:05 p.m. QUESTIONS AND ANSWERS
- 5:10 p.m. PANEL DISCUSSION
- 5:45 p.m. ADJOURNMENT
- 6:30 p.m. RECEPTION
- 7:30 p.m. PRESENTATION OF THE ALBERT B. SABIN GOLD MEDAL

## Wednesday, May 8, 2002

- 7:00 a.m.- 8:00 a.m. REGISTRATION
- 7:30 a.m. CONTINENTAL BREAKFAST

## SYMPOSIUM 6: HUMAN PAPILLOMAVIRUS

- 8:00 a.m. EPIDEMIOLOGY, BASIC BIOLOGY AND CLINICAL IMPLICATIONS  
Harold zur Hausen, Ph.D., D.Sc.  
*Deutsches Krebsforschungszentrum*
- 8:15 a.m. QUESTIONS AND ANSWERS
- 8:20 a.m. FDA VIEW ON ENDPOINTS FOR PHASE III TRIALS  
Karen Goldenthal, M.D.  
*U.S. Food and Drug Administration*
- 8:35 a.m. QUESTIONS AND ANSWERS

# on Vaccine Research

8:40 a.m. TRIALS OF PREVENTIVE VACCINES  
John T. Schiller, Ph.D.  
*National Cancer Institute*

8:55 a.m. QUESTIONS AND ANSWERS

9:00 a.m. STATUS OF PROPHYLACTIC VACCINES  
AGAINST CERVICAL CANCER  
Kathrin Jansen, Ph.D.  
*Merck & Co., Inc.*

9:15 a.m. QUESTIONS AND ANSWERS

9:20 a.m. CURRENT STATUS OF THERAPEUTIC VACCINES  
Drew Pardoll, M.D., Ph.D.  
*Johns Hopkins University  
School of Medicine*

9:35 a.m. QUESTIONS AND ANSWERS

## SUBMITTED PRESENTATIONS

9:45 a.m. CONCURRENT SUBMITTED PRESENTATIONS

10:30 a.m. COFFEE BREAK

11:00 a.m. CONCURRENT SUBMITTED PRESENTATIONS

12:15 p.m. LUNCH

## SYMPOSIUM 7: NEW VACCINE TECHNOLOGIES

1:30 p.m. APPLICATION OF GENE SHUFFLING TECHNOLOGY TO  
VACCINE DEVELOPMENT  
Russell J. Howard, Ph.D.  
*Maxygen, Inc.*

1:45 p.m. QUESTIONS AND ANSWERS

1:50 p.m. NOVEL VIRAL VECTORS  
Hildegund C. Ertl, M.D.  
*Wistar Institute*

2:05 p.m. QUESTIONS AND ANSWERS

2:10 p.m. VACCINE DEVELOPMENT IN TRANSGENIC ANIMALS  
Harry M. Meade, Ph.D.  
*Genzyme Transgenics*

2:25 p.m. QUESTIONS AND ANSWERS

2:30 p.m. REGULATORY ISSUES FOR NEW VACCINE  
TECHNOLOGIES  
Jon R. Daugherty, Ph.D.  
*U.S. Food and Drug Administration*

2:45 p.m. QUESTIONS AND ANSWERS

2:50 p.m. COFFEE BREAK

## SYMPOSIUM 8: PRACTICAL ISSUES IN CLINICAL TRIALS

3:20 p.m. ASSESSING VACCINE SAFETY IN PRE-LICENSURE  
CLINICAL TRIALS: AN INDUSTRY PERSPECTIVE  
George R. Siber, M.D.  
*Wyeth Lederle Vaccines*

3:35 p.m. QUESTIONS AND ANSWERS

3:40 p.m. ASSESSING VACCINE SAFETY IN PRE-LICENSURE  
CLINICAL TRIALS: A REGULATORY AGENCY  
PERSPECTIVE  
Karen Midthun, M.D.  
*U.S. Food and Drug Administration*

3:55 p.m. QUESTIONS AND ANSWERS

4:00 p.m. VACCINE TRIALS AND THE ASSESSMENT  
OF HERD IMMUNITY  
Paul E.M. Fine, M.Sc., D.Sc.  
*London School of Tropical  
Medicine & Hygiene*

4:15 p.m. QUESTIONS AND ANSWERS

4:20 p.m. CONTENTIOUS ETHICAL ISSUES IN PERFORMING  
CLINICAL VACCINE TRIALS IN DEVELOPING  
COUNTRIES: A BIOETHICIST'S PERSPECTIVE  
Charles Weijer, M.D., Ph.D.  
*Dalhousie University*

4:35 p.m. QUESTIONS AND ANSWERS

4:40 p.m. PARTICIPANT EVALUATION

4:45 p.m. ADJOURNMENT

\* SPEAKERS AND PRESENTATIONS ARE SUBJECT TO CHANGE

# The Fifth Annual Conference

## Registration and Fees

### THE REGISTRATION FEES ARE AS FOLLOWS:

On or before March 22, 2002*	\$350
After March 22, 2002 and Onsite	\$400

\*To qualify for the reduced registration fee of \$350, a **completed registration form with payment** must be received at the NFID office before 5 p.m. Eastern Time on March 22, 2002. Registrations or payments received after March 22 will be subject to the \$400 fee.

The registration fee includes a program/abstract book, continental breakfast on each day of the conference, coffee breaks, and receptions. Accommodations and additional meals are not included.

Follow the registration instructions below according to your method of payment. Confirmation letters will be sent within two weeks of completed registration and proper payment. **Please allow time for processing.**

- **Credit Cards:** If you are paying by credit card, you may register securely online at <http://www.nfid.org>, fax your registration to 1-301-907-0878 or mail it to the address below. We are unable to accept telephone registrations.
- **Check or Money Order:** Checks (drawn on a U.S. bank only) and/or money orders must be in U.S. dollars, made payable to NFID, and mailed with the registration form to the address below.

Purchase orders can not be accepted.

Send registrations to the following address:

**Fifth Annual Conference on Vaccine Research**  
National Foundation for Infectious Diseases  
4733 Bethesda Avenue, Suite 750  
Bethesda, MD 20814-5278 USA

*Registrations received after April 26  
will be processed on-site.*

## CANCELLATION POLICY

Refunds minus a \$75 administrative fee will be granted only if *written notification* arrives at the NFID office prior to 5 p.m. Eastern Time on March 29, 2002. There will be no refunds for cancellations made after March 29, 2002. NFID reserves the right to cancel this conference at any time. In the event of conference cancellation, only the full registration fee will be returned to the registrant.

## FOR FURTHER INFORMATION

Please contact Lisa Gaylord or Kathleen Hanrahan through any of the means listed below:

### **Mail:**

Fifth Annual Conference on Vaccine Research  
National Foundation for Infectious Diseases  
4733 Bethesda Avenue, Suite 750  
Bethesda, MD 20814-5278 USA

**Phone:** 301-656-0003 x19

**Fax:** 301-907-0878

**E-Mail:** [vaccine@nfid.org](mailto:vaccine@nfid.org)

**Visit our Website:** <http://www.nfid.org/conferences>

# on Vaccine Research

## Registration Form

FIFTH ANNUAL CONFERENCE  
ON VACCINE RESEARCH

MAY 6–8, 2002

WYNDHAM BALTIMORE INNER HARBOR  
BALTIMORE, MD

*(Please print clearly or type; photocopy for additional registrants.)*

\_\_\_\_\_

last name first name middle initial

\_\_\_\_\_

professional title affiliation

primary degree(s) (circle all that apply):

MS MA BS BA MD PhD DSc DPH Other \_\_\_\_\_

\_\_\_\_\_

primary specialty (e.g., immunology, infectious diseases, clinical research, etc.)

\_\_\_\_\_

mailing address

\_\_\_\_\_

city state zip+4/postal code

\_\_\_\_\_

country

\_\_\_\_\_

daytime telephone fax number

\_\_\_\_\_

e-mail address

- I do not wish my contact information to appear on the Conference Participant List to be distributed at the conference.

### SPECIAL NEEDS

Please list any special meeting needs or requirements you may have in the space below, or contact Kathleen Hanrahan at (301) 656-0003 x19 or vaccine@nfid.org:

\_\_\_\_\_

\_\_\_\_\_

## PAYMENT



\$350 Early Bird Fee (through March 22)

\$400 (after March 22)

- Please include a receipt with my confirmation materials.

- Check or money order drawn on U.S. funds (**made payable to NFID**) enclosed in the amount of \$\_\_\_\_\_.

- Please bill my credit card in the amount of \$\_\_\_\_\_.

Check type of card:

- Visa  MasterCard  American Express

\_\_\_\_\_

name as printed on card

\_\_\_\_\_

card number expiration date

\_\_\_\_\_

signature

\_\_\_\_\_

billing address (if different from registrant's mailing address)

\_\_\_\_\_

city state zip+4/postal code

\_\_\_\_\_

country

## FOR FURTHER INFORMATION

Please contact Lisa Gaylord or Kathleen Hanrahan at the address listed below:

Fifth Annual Conference on Vaccine Research  
National Foundation for Infectious Diseases  
4733 Bethesda Avenue, Suite 750  
Bethesda, MD 20814-5278 USA

Phone: 301-656-0003 x19 Fax: 301-907-0878

E-Mail: vaccine@nfid.org



